Advanced Medical Solutions Group plc
("AMS", the "Company"
or the "Group")
Director/PDMR Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS),
the world-leading specialist in tissue-healing
technologies, announces the following Director share transactions.
As part of the Share Incentive Plan
("SIP"), previously referred to as the Deferred Share Bonus Plan
("DSB"), Executive Directors and employees can sacrifice part of
their annual bonus and/or salary in the SIP, which for every share
purchased on behalf of the employee they receive matching shares
which are deferred for a minimum of three years. Chris Meredith
(CEO) and Eddie Johnson (CFO) have elected to sell certain existing
shares to use the proceeds to re-invest in the SIP.
The Company was notified on 11 November 2024 that following his decision
to participate Chris Meredith, who is a Director and PDMR,
executed the sale 29,199
Ordinary Shares of 5p from the
existing SIP on 11
November 2024 at a share price of
218.37p per Ordinary
Share. The proceeds from the sale of the
shares were used to purchase shares in the SIP, as detailed
below.
The Company was further notified on 11 November 2024 that following his
decision to participate Eddie Johnson, who is a Director and PDMR,
executed the exercise of 34,235 options
from the existing Long Term Incentive Plan ("LTIP")
and subsequently sold
34,235 Ordinary Shares of 5p each on 11 November 2024
at a share price of 217.58p per Ordinary Share.
The proceeds from the sale of the shares were used
to purchase shares in the SIP, as detailed below.
The number of shares held by Eddie Johnson and his
PCAs will increase his beneficial interest in the
Company from the level prior to these
transactions.
The Trust which manages the SIP on
behalf of the employees of AMS has purchased Ordinary Shares of 5p
each ("Ordinary Shares") on 12 November 2024, at a share price of
224.50p on behalf of Chris Meredith (26,089 Ordinary Shares) and
Eddie Johnson (17,229 Ordinary Shares), who are both
Directors/PDMRs, as part of the SIP and, under the terms of the
SIP, these shares will be held in trust on their behalf.
Following these transactions the
beneficial ownership of Chris Meredith and Eddie Johnson are as
follows:
|
Director/PDMR
|
Date purchased
|
Shares purchased (through
SIP)
|
Resultant holding
|
% of issued share capital
|
|
Chris Meredith
Chief Executive Officer
|
12 November 2024
|
26,089
|
1,817,211
|
0.83%
|
|
Eddie Johnson
Chief Financial Officer
|
12 November 2024
|
17,229
|
169,731
|
0.08%
|
The notification below, made in
accordance with the requirements of the EU Market Abuse Regulation,
provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1.
|
Details of the person discharging
managerial responsibilities/person closely
associated
|
|
a)
|
Name: Chris Meredith
|
2.
|
Reason for the
notification
|
|
a)
|
Position/status: Chief
Executive Officer
|
|
b)
|
Initial
notification/Amendment: Initial Notification
|
3.
|
Details of the issuer, emission
allowance market participant, auction platform, auctioneer or
auction monitor
|
|
a)
|
Name:
Advanced Medical Solutions Group plc
|
|
b)
|
LEI: 213800HJP6OWOSZI1L74
|
4.
|
Details of the transaction(s): section
to be repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
|
a)
|
Description of the
financial instrument, type of instrument: Ordinary Shares of
5p
Identification code:
GB0004536594
|
|
b)
|
Nature of the
transactions:
·
Sale of Ordinary Shares of 5p Share
Incentive Plan
·
Purchase of Ordinary Shares as part of the Share Incentive Plan on 12 November
2024
|
|
c)
|
Price(s) and
volume(s):
|
Price(s)
|
Volume(s)
|
|
Sale of shares from
SIP at 218.37p per share
|
29,199
|
|
Purchase by SIP at
224.50p per share
|
26,089
|
|
|
d)
|
Aggregated
information:
Aggregated volume:
n/a
Aggregated price:
n/a
|
|
e)
|
Date of the
transactions: 11/11/2024 and 12/11/2024
|
|
f)
|
Place of the
transaction: London Stock Exchange
(XLON)
|
1.
|
Details of the person discharging
managerial responsibilities/person closely
associated
|
|
a)
|
Name: Eddie Johnson
|
2.
|
Reason for the
notification
|
|
a)
|
Position/status: Chief
Financial Officer
|
|
b)
|
Initial
notification/Amendment: Initial Notification
|
3.
|
Details of the issuer, emission
allowance market participant, auction platform, auctioneer or
auction monitor
|
|
a)
|
Name:
Advanced Medical Solutions Group plc
|
|
b)
|
LEI: 213800HJP6OWOSZI1L74
|
4.
|
Details of the transaction(s): section
to be repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
|
a)
|
Description of the
financial instrument, type of instrument: Ordinary Shares of
5p
Identification code:
GB0004536594
|
|
b)
|
Nature of the
transactions:
·
Exercise of options from the LTIP
·
Sale of Ordinary Shares of
5p
·
Purchase of Ordinary Shares as part of the Share Incentive Plan on 12 November
2024
|
|
c)
|
Price(s) and
volume(s):
|
Price(s)
|
Volume(s)
|
|
Exercise of options
from LTIP at nil cost
|
34,235
|
|
Sale of shares
at 217.58p per share
|
34,235
|
|
Purchase by SIP at
224.50p per share
|
17,229
|
|
|
d)
|
Aggregated
information:
Aggregated volume:
n/a
Aggregated price:
n/a
|
|
e)
|
Date of the
transactions: 11/11/2024 and 12/11/2024
|
|
f)
|
Place of the
transaction: London Stock Exchange
(XLON)
|
- Ends -
For
further information, please visit www.admedsol.com
or
contact:
|
Advanced Medical Solutions Group plc
|
Tel: +44
(0) 1606 545508
|
|
Chris Meredith, Chief Executive
Officer
Eddie Johnson, Chief Financial
Officer
Michael King, Investor
Relations
|
|
|
|
|
|
ICR
Consilium
|
Tel: +44
(0) 20 3709 5700
|
|
Mary-Jane Elliott
/ Lucy
Featherstone
|
AMS@consilium-comms.com
|
|
|
|
|
Investec Bank PLC (NOMAD & Broker)
|
Tel: +44
(0) 20 7597 5970
|
|
Gary Clarence / David
Anderson
|
|
|
|
|
|
HSBC Bank PLC (Broker)
|
Tel: 44
(0) 20 7991 8888
|
|
Joe Weaving / Stephanie
Cornish
|
|
About Advanced Medical Solutions Group plc
-
see www.admedsol.com
AMS is a world-leading independent
developer and manufacturer of innovative tissue-healing technology,
focused on quality outcomes for patients and value for payers. AMS
has a wide range of surgical products including tissue adhesives,
sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand®, RESORBA®,
LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and
Seal-G®. AMS also supplies wound care dressings such as silver
alginates, alginates and foams through its ActivHeal® brand as well
as under white label. Since 2019, the Group has made seven
acquisitions: Sealantis, an Israeli developer of innovative
internal sealants, Biomatlante, a French developer and manufacturer
of surgical biomaterials, Raleigh, a leading UK coater and
converter of woundcare and bio-diagnostics materials, AFS Medical,
an Austrian specialist surgical business, Connexicon, an Irish
tissue adhesives specialist, Syntacoll, a German specialist in
collagen-based absorbable surgical implants and Peters Surgical, a
global provider of specialty surgical sutures, mechanical
haemostasis and internal cyanoacrylate devices.
AMS's products, manufactured in the
UK, Germany, France, the Netherlands, Thailand, India, the Czech
Republic and Israel, are sold globally via a network of
multinational or regional partners and distributors, as well as via
AMS's own direct sales forces in the UK, Germany, Austria, France,
Poland, Benelux, India, the Czech Republic and Russia. The Group
has R&D innovation hubs in the UK, Ireland, Germany, France and
Israel. Established in 1991, the Group has more than 1,500
employees. For more information, please see
www.admedsol.com.